

## Special Issue

# Advances in Drug Discovery and Development Using Mass Spectrometry

### Message from the Guest Editors

Proteomics-based methods are widely used across the pharmaceutical industry, aiming to identify, characterize, and/or quantify new drug therapeutics. In the early stages of research, exploratory proteomic strategies enable scientists to focus in on significant signaling pathways and identify protein targets crucial to disease states. Later in the process, once potential candidates are identified, efforts to characterize them through assessing critical quality attributes for developability highlight the risks and benefits of potential programs. Once a candidate is considered desirable for the development investment, targeted proteomic approaches can provide the drug's pharmacokinetics or quantify relevant biomarkers in a highly regulated environment. The proteomics field has had a strong impact, from idea to filing, on the pharmaceutical industry and continues to grow as new innovative techniques are revealed. Acknowledging the diverse utility of proteomics to pharmaceutical sciences, I invite authors to submit original research and review articles on the topic: Advances in Drug Discovery and Development Using Mass Spectrometry.

### Guest Editors

Dr. Emily G. Werth

Dr. Amirata Saei Dibavar

Dr. Lin-Zhi Chen

### Deadline for manuscript submissions

31 May 2026



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/217201](https://mdpi.com/si/217201)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).